Get the Stockscreener App
0.0905
1.80%
0.0016
Pre-market:
.09
-0.0005
-0.55%
Nucana Plc Adr stock is traded at $0.0905, with a volume of 64.40M.
It is up +1.80% in the last 24 hours and up +138.16% over the past month.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
See More
Previous Close:
$0.0889
Open:
$0.09
24h Volume:
64.40M
Relative Volume:
0.51
Market Cap:
$869.17K
Revenue:
-
Net Income/Loss:
$-33.44M
P/E Ratio:
-0.00565
EPS:
-16.0242
Net Cash Flow:
$-28.30M
1W Performance:
-26.78%
1M Performance:
+138.16%
6M Performance:
-92.49%
1Y Performance:
-96.94%
1-Day Range:
$0.08
$0.0978
1-Week Range:
$0.0646
$0.136
52-Week Range:
$0.0325
$10.79
Nucana Plc Adr Stock (NCNA) Company Profile
Compare NCNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NCNA
Nucana Plc Adr
|
0.0905 | 869.17K | 0 | -33.44M | -28.30M | -16.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-03-22 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-22-20 | Initiated | Truist | Buy |
| Jul-24-20 | Initiated | Oppenheimer | Outperform |
| Aug-19-19 | Initiated | H.C. Wainwright | Buy |
| Oct-19-18 | Initiated | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | Citigroup | Buy |
| Oct-23-17 | Initiated | Jefferies | Buy |
| Oct-23-17 | Initiated | William Blair | Outperform |
View All
Nucana Plc Adr Stock (NCNA) Latest News
NuCana CEO takes leave of absence due to health reasons - Investing.com
Market Insight: RxSight Inc (RXST)’s Notable Drop, Closing at 13.50 - DWinneX
The Future of NuCana plc ADR: Analyzing NCNA - investchronicle.com
nucana plc announces annual report release and upcoming agm By Investing.com - Investing.com India
nucana plc announces annual report release and upcoming agm - Investing.com
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
NuCana prices $7 million direct offering of ADSs and warrants - Investing.com
NuCana prices $7 million direct offering of ADSs and warrants By Investing.com - Investing.com India
New Outlook On NuCana plc ADR - Stocksregister
NCNA’s Stock Journey: What Investors Need to Know About NuCana plc ADR’s Performance - investchronicle.com
Do investors need to be concerned about Cadiz Inc (CDZI)? - uspostnews.com
Natera Inc (NTRA) deserves closer scrutiny - uspostnews.com
Weave Communications Inc (WEAV) produces promising results - uspostnews.com
Investing in NuCana plc ADR (NCNA) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Nasdaq
Post-Trade Analysis: NuCana plc ADR (NCNA) Slides -26.97, Closing at 0.65 - DWinneX
Closing Bell Recap: Yxt.Com Group Holding Ltd. ADR (YXT) Ends at 0.56, Reflecting a -14.42 Downturn - DWinneX
In the Green: Gogoro Inc (GGR) Closes at 0.26, Up/Down 0.08 from Previous Day - DWinneX
Daily Market Movement: Tivic Health Systems Inc (TIVC) Sees a 1.88 Increase, Closing at 7.04 - DWinneX
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Barchart.com
Stock Update - Investorsobserver
NuCana Reports Strong Phase 2 Data: 75% Disease Control in Melanoma Trial, Lower Q3 Loss - StockTitan
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NuCana stock downgraded by William Blair after halted cancer study - Investing.com
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks - Yahoo Finance
Down 57.3% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) - Nasdaq
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session - Yahoo Finance
Cboe U.S. Equities Exchanges Overview - Cboe Global Markets
Will NuCana Continue to Surge Higher? - Nasdaq
NuCana (NCNA) Stock Price, News & Analysis - MarketBeat
NCNA Stock Price and Chart — NASDAQ:NCNA - TradingView
NuCana PLC Stock Price Today | NASDAQ: NCNA Live - Investing.com
Nucana Plc Adr Stock (NCNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):